Target intelligence / Profile preview

KCNQ family potassium channel (KCNQ (Kv7) channel)

Target
KCNQ (Kv7) channel
Molecular classification
Ion channel, Voltage-gated potassium channel
01

Overview

The **KCNQ family potassium channels** (Kv7.1–Kv7.5) are voltage-gated potassium channels that form tetrameric pores in cell membranes, enabling selective potassium efflux critical for regulating membrane potential in excitable cells. These channels are essential in multiple tissues, including the heart (where KCNQ1 mediates cardiac repolarization), brain (KCNQ2/3/5 contribute to neuronal M-current), and inner ear (KCNQ4 is necessary for normal auditory function). KCNQ channels are modulated by a variety of endogenous factors (such as phosphatidylinositol bisphosphate and calmodulin), and their function can be altered by disease mutations or pharmacological agents. Pathogenic mutations in these channels are implicated in cardiac arrhythmias (such as Long QT syndrome), epilepsy, and sensorineural deafness, making them significant therapeutic targets in neurology and cardiology[1][2][3][4][5][6][7].

Other names
Kv7 channelKv7.1–Kv7.5M-channelKCNQ1-5voltage-gated potassium channel subtype 7
02

Mechanism of action

KCNQ channel openers (increase channel activity to reduce neuronal excitability) - KCNQ channel blockers (decrease channel activity to increase neuronal excitability or prolong action potential) - Modulation of channel activity by altering voltage sensitivity and gating properties

03

Biological functions

Regulation of membrane potentialControl of neuronal excitabilityCardiac repolarizationHearing (auditory transduction)Epithelial ion homeostasis
04

Disease associations

Cardiac arrhythmia (including Long QT syndrome, familial atrial fibrillation)Epilepsy (including benign familial neonatal convulsions)Sensorineural hearing loss/deafnessCardiovascular diseaseNeurodegenerative disease (implicated, but less direct evidence)
05

Safety considerations

Risk of cardiac arrhythmia (potential for proarrhythmic effect)CNS side effects (e.g., confusion, somnolence with retigabine)Hearing loss (genetic mutations or off-target inhibition)Potential for drug-induced QT prolongation
06

Interacting drugs

Retigabine (Ezogabine)

4 more in the full profile.

07

Biomarkers

Mutations in KCNQ1, KCNQ2, KCNQ3, KCNQ4 as genetic markers for disease risk (e.g., Long QT syndrome, benign familial neonatal convulsions)Electrocardiogram (QT interval prolongation as an indicator of KCNQ1 channel dysfunction)

Beyond the preview

Go deeper on KCNQ family potassium channel (KCNQ (Kv7) channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KCNQ family potassium channel (KCNQ (Kv7) channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call